Diurnal salivary androstenedione and 17‐hydroxyprogesterone levels in healthy volunteers for monitoring treatment efficacy of patients with congenital adrenal hyperplasia

OBJECTIVE: Treatment of congenital adrenal hyperplasia (CAH) patients with glucocorticoids is often challenging since there is a delicate balance between over‐ and undertreatment. Treatment can be monitored noninvasively by measuring salivary androstenedione (A4) and 17‐hydroxyprogesterone (17‐OHP)....

Descripción completa

Detalles Bibliográficos
Autores principales: Adriaansen, Bas P. H., Kamphuis, Johannes S., Schröder, Mariska A. M., Olthaar, André J., Bock, Carina, Brandt, André, Stikkelbroeck, Nike M. M. L., Lentjes, Eef G. W. M., Span, Paul N., Sweep, Fred C. G. J., Claahsen‐van der Grinten, Hedi L., van Herwaarden, Antonius E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542109/
https://www.ncbi.nlm.nih.gov/pubmed/35150157
http://dx.doi.org/10.1111/cen.14690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542109/
https://www.ncbi.nlm.nih.gov/pubmed/35150157
http://dx.doi.org/10.1111/cen.14690

Ejemplares similares